Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Man. I’m going to sit back for the next 3 months buying every chance I get money until this passes 20. This is a x 5 under 20 within a year from now. 17s please x6 would be nice. Why even waste time discussing stuff. Literally just sit back and buy. The longer this stays down the more we can buy. We are so lucky to be here and understand what’s developing. Obviously most people aren’t because of the manipulation.
Robin. Still checking here? I keep adding. So many clinicians are going to get rich. Was this a gift to us for working during pandemic?
If trend continues like this to Friday close and close above 21. EUA app news should be Monday.
Yep. But that is why I am here. Because he is straight as an arrow and honest on timelines. If things were all over the place I wouldn’t trust adding on this dip. Only surprise I will have in coming months is if they don’t get bought out. Too much for an 8 person team with crappy contractors. And yes this should be going worldwide. I believe this is order of attack
1) USA
2) South Korea/Phillipines
3) UK
3) EU
4) Australia
5) Canada
6) Japan
7) Russia
8) India
9) Mexico
I’m looking at who uses Tocilizumab and Remesdivir FYI
Galleo or whatever the HIV guys name is, was talking most likely about CD14 drug that was just announce for a phase 2 NIH. It’s being done at Maryland Med where he works. But he still could mean Lenzilumab Bc GM-CSF is directly correlated with CD14. They didn’t get to CD14 without Lenzilumab. Hang on guys. Going to be a fun ride!
3 weeks starts next week. 2-3 weeks of meeting with FDA per CEO. (Pre pandemic is 4 weeks). Should get PR of EUA submission this week or next Monday. I wouldn’t be surprise if it’s Monday after coming. Shorts and everyone know this. They also know this management doesn’t pump and does things strictly by the book. Should trend up next week. But expect Friday to see massive covering of no news next week.
Sorry I haven’t posted in awhile. I was busy selling everything I can to buy more shares. This is going to be one for the history books
Yes whole study halt was an error by clinicaltrial.gov site. They most likely meant to suspended just one site or two. Someone contacted them and they said their was a brief manufacturing issues at one of the sites and only needed a temporary suspension. From what it sounds like, someone made an error at NIH and they want to cover themselves.
EUA data worthy for sure. Secondary end points will confirm this to media. It’s up to manufacturing at this point. I was more worried about manufacturing than results to be honest. All that matters is the drug works. The flood gates are open for drug. It’s now worth A LOT of money!
The buyout depends on lymphocyte count in my opinion :)
Pump and dump???????
Are you kidding. Did you not see the results Monday. This is getting EUA. This is a manufacturing issue and I knew there would be a manufacturing issue from ACTIV halt. This fixes it. So much news coming. This is going to explode!
If you don’t think HGEN doesn’t have a PR coming on Thursday or Monday morning for secondary end points you have no idea what’s going on. This will be 30+ by Tuesday. I’m buying today! So many shorts are going to cover LOL. That’s so much cash that they didn’t need unless they have massive manufacturing coming
Just buy HGEN dude. Your here Bc news is huge here. Stop fighting it. You can buy and have puts as your safety net. But if your in a failing CYDY no one will take you serious. Company is a complete scam. Long hauler study already failed based on endpoints. It’s a joke. A questionnaire for primary end point. No exclusion of vaccines which is leading in ending long haulers. Also just phase 2. You won’t get EUA for long haulers for phase 3. It’s a whole BLA. You would be talking two years but once again study is already fail. Critical is just a scam to continue it when long haulers news fails.
They sold 1million plus shares with a 20 avg sp. They raised 31.2 million from Cantor ATM.
You are about to find out This week how significant CYDY trial failure and holding data for weeks means to HGEN. Like I said. I understood the science and many shorting did as well. They will be adding here this week with profits
Jay. They have a 2:1 ratio 43 Leronlimab to 19 placebo. P value is 0.4. Pure by chance. For example if 3 less people died in placebo, they would have better mortality. They also didn’t release that actual mortality % which is weird. Also they just stated that they missed every single end point which is why they are cherry picking everything. That drug is completely out of the picture.
The science and signs was there to short CYDY with a 5% risk. I wouldn’t be surprised if people that were shorting it will get out and then buy HGEN. I wish I shorted them at 5. I was about to sell all HGEN to short it Bc it was so obvious with almost no risk. Then buy back in HGEN once it hit 2.5 for CYDY.
If HGEN brings some news Monday morning this thing will fly
Jay I’m proud of your for selling CYDY. You of all people deserve the right timing and choice
Leronlimab missed primary and 4 secondary end points. That’s pretty bad. They had good critical results with 60 patients for vents. But then again. 1-2 more death in placebo would get it 24% difference. They will need to do a critical study if they want hope. Severe data must be horrendous. That stock should drop 50% Monday
Wait till you get the vaccine. It will be worse lol
Humanigen was just brought up by Cramer with Emergent CEO. CEO said he’s glad he did. Bring it up. It’s coming!
The big drop today was same time GME spiked. That’s was weird but we do have big holders here who are in GME as well
Also have to factor how Lenzilumab buyout will be astronomical. No strings attached. You see that with every move. Buy and use.
The fact they wrote that and released it when the market tanked in this sector is suspect. I really hope Cantor and a Durrant fire back Friday with some news. What’s analyst name?
BET A is same trial. Whatever updates they have it’s for BET B. Btw. BET A has Yale on it. Can’t wait till it says RECRUITING.
I’m just coming here to RANTE pure frustration.
I listen to that Bruce Patterson long hauler webinar. It had a bunch of long hauler women in chat. He basically told them, I don’t need to do anymore studies I don’t need funding from NIH I know this works. Just take it and trust me.
It’s frustrating to hear. Long haulers( POST COVID SYNDROME) is a multidisciplinary approach that will not get fixed from just medication. (Low dose steroids like prednisone is working at Hopkins and Boston Mass to normalize those with elevated inflammatory markers). Problem is damage from inflammation and medication like dexamethsone.
These people have heart damage, lung damage, kidney damage, liver damage, brain damage. The whole system is out of whack! These people need to see a variety of specialist based on symptoms!!
Cardiologist, pulmonologist, ENT, Neurologist, physiatrist, psychiatrist, psychologist, physical therapy, endocrinologist, rheumatologist.
I really hope Mayo Clinic develops a good program. Rehabilitation is HUGE in this population
Robin. I’m all in. Research there. I don’t see how it doesn’t get approved. Best lottery ticket
Scooter Citadel is invested in HGEN. They aren’t shorting it. :)
Unemployment numbers were pretty bad. Hopefully market doesn’t go before our news. I am still nervous about market when variant wave comes. I would go light on market in late March to May.
Basically Durrant is saying COVID is here to stay. And expect spikes after Spring break. Also said Uk will be dominant in April
I couldn’t get registered. Says pending. Anything new please post. Or when presentation available. Thanks ladies and gentlemen! Can’t wait till this is breaking news
Link for conference today?
After hours SP was weird here. It went up like 5% then gradual decline like the day in after hours
We will have a better idea coming Friday I anticipate. I think same week early on until Friday. Not based on anything but guessing lol
They did get 26 million for NIH ACTIV V trial
Equilium crashing after GVHD. Read more tonight. Lenzilumab!
I mean they were released a few weeks ago. It just hit mainstream media yesterday on all levels. 4% improvement in mortality. I’m sure there is a lot of improvement elsewhere. Need to read full published study when out
If it ever gets released. They def have enough information by now for the PR on results. I would say today, Friday. Will be the day. But def no later than Tuesday next week.
Seriously. Certain study design you know drugs won’t get EUA even with meeting end points based on design. I saw it with Relief as well.
Check out Bruce P study of leronimab for severe critical. I never went to the table with all 10 patients.
In 14 days. 4 of the 10 died. 2 still were still intubated. 1 was DC (never vented on 2L O2) hahaha!, 1 went from intubated to room air but still admitted. And last 2 just says still admitted improve but doesn’t say how or change in O2 supplementation device
https://www.ijidonline.com/article/S1201-9712(20)32305-5/fulltext
I honestly feel bad for CYDY investors. On their forums they started pumping the 30% being the SOC mortality based on RLFTF trial. It’s pumped so bad it’s scary. Could fool anyone. Even saying RLFTF took no vents.
RLFTF trial was strictly CRITICAL ICU patients with ventilation. They were also saying how Tocilizumab lowered mortality only 4% but failed to realize it was also just CRITICAL ICU and they are posting the old April -July 2020 severe study and not UK critical one.
Tocilizumab study for severe during April-July had mortality for SOC at 27%. As we know. Death rates at that time were around 10% more during that time of pandemic. So I would say mortality for SOC to be safe right now for SEVERE is 15% especially factoring in Lilly Regeneron use and even covalent plasma use being started after Tocilizumab severe trial.
If CYDY study was balanced with severe and critical it would go like this. Severe 15% mortality mixed with critical 30% mortality sits that sucker at 22.5% avg mortality ESPECIALLY since they allowed Tocilizumab and neutralizing MABs to be apart of the study as standard of care.
But this is same reason lenzilumab did not want mortality end point. It’s too much of a difference between severe and critical mortality percentages. Also too much of a change for a drug performed over several months with SOC is constantly improving.
Ya. I believe at time of start. Mayo Clinic was using on everyone and knew it would be EUA. I’m still shocked most people are missing the fact Mayo Clinic got plasma EUA and ignoring lenzilumab. Especially after Tocilizumab
Robin. Did you notice how exclusion for Lenzilumab phase 3 included taking Regeneron and Eli Lilly MABs. That’s why it was so hard to complete trial. Mayo Clinic was def the hospital system that use the MABs the most!